Literature DB >> 19048111

A mammary-specific, long-range deletion on mouse chromosome 11 accelerates Brca1-associated mammary tumorigenesis.

Aleata A Triplett1, Cristina Montagna, Kay-Uwe Wagner.   

Abstract

We engineered a mammary-specific knockout model for Brca1 deficiency that also lacks the majority of one chromosome 11 to determine whether tumor susceptibility loci reside on this chromosome that cooperate with the loss of Brca1 during mammary cancer formation. Brca1-deficient females that are haploinsufficient in 60 cM of chromosome 11 exhibited accelerated mammary tumorigenesis in comparison to Brca1 conditional knockout mice. On the histopathologic level, these tumors were either adenocarcinomas or benign, inflammatory lesions. Like human BRCA1-associated breast cancers, mammary carcinomas in this new mouse model were ERalpha-negative and of basal epithelial origin. Brca1 deficiency and haploinsufficiency in 60 cM of chromosome 11 caused widespread genome instability as determined by spectral karyotyping analysis. In addition to the verification of the long-range deletion event, the spectral karyotyping analysis revealed that the duplication of the genome and higher degree of aneuploidy occur rather late in tumor progression. Despite chromosomal rearrangements near the Trp53 locus as determined by fluorescence in situ hybridization, the Trp53 gene was transcriptionally active. The analysis of the coding sequence and expression pattern of p53 and p21 suggests that loss-of-heterozygosity of Trp53 caused by somatic mutations contributes to accelerated mammary tumorigenesis in this model.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048111      PMCID: PMC2586683          DOI: 10.1593/neo.08524

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  34 in total

1.  Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3.

Authors:  R S Chapman; P C Lourenco; E Tonner; D J Flint; S Selbert; K Takeda; S Akira; A R Clarke; C J Watson
Journal:  Genes Dev       Date:  1999-10-01       Impact factor: 11.361

2.  A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer.

Authors:  R J Osborne; M G Hamshere
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

3.  Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice.

Authors:  K U Wagner; K McAllister; T Ward; B Davis; R Wiseman; L Hennighausen
Journal:  Transgenic Res       Date:  2001-12       Impact factor: 2.788

4.  Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland.

Authors:  J Russo; X Ao; C Grill; I H Russo
Journal:  Breast Cancer Res Treat       Date:  1999-02       Impact factor: 4.872

5.  Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women.

Authors:  S Noguchi; T Kasugai; Y Miki; T Fukutomi; M Emi; T Nomizu
Journal:  Cancer       Date:  1999-05-15       Impact factor: 6.860

6.  Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.

Authors:  S G Brodie; X Xu; W Qiao; W M Li; L Cao; C X Deng
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

7.  Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region.

Authors:  F Magdinier; S Ribieras; G M Lenoir; L Frappart; R Dante
Journal:  Oncogene       Date:  1998-12-17       Impact factor: 9.867

8.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.

Authors:  X Xu; K U Wagner; D Larson; Z Weaver; C Li; T Ried; L Hennighausen; A Wynshaw-Boris; C X Deng
Journal:  Nat Genet       Date:  1999-05       Impact factor: 38.330

9.  Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer.

Authors:  L P Jones; M T Tilli; S Assefnia; K Torre; E D Halama; A Parrish; E M Rosen; P A Furth
Journal:  Oncogene       Date:  2007-07-23       Impact factor: 9.867

10.  Oxytocin and milk removal are required for post-partum mammary-gland development.

Authors:  K U Wagner; W S Young; X Liu; E I Ginns; M Li; P A Furth; L Hennighausen
Journal:  Genes Funct       Date:  1997-11
View more
  8 in total

1.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

2.  Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.

Authors:  Sonia de Assis; Anni Warri; Carlos Benitez; William Helferich; Leena Hilakivi-Clarke
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

3.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Authors:  K Sakamoto; A A Triplett; L A Schuler; K-U Wagner
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

5.  In vivo tumorigenesis was observed after injection of in vitro expanded neural crest stem cells isolated from adult bone marrow.

Authors:  Sabine Wislet-Gendebien; Christophe Poulet; Virginie Neirinckx; Benoit Hennuy; James T Swingland; Emerence Laudet; Lukas Sommer; Olga Shakova; Vincent Bours; Bernard Rogister
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

6.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

7.  Generation of a novel MMTV-tTA transgenic mouse strain for the targeted expression of genes in the embryonic and postnatal mammary gland.

Authors:  Kazuhito Sakamoto; Jeffrey W Schmidt; Kay-Uwe Wagner
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

8.  Novel transcripts from a distinct promoter that encode the full-length AKT1 in human breast cancer cells.

Authors:  Jeffrey W Schmidt; Barbara L Wehde; Kazuhito Sakamoto; Aleata A Triplett; William W West; Kay-Uwe Wagner
Journal:  BMC Cancer       Date:  2014-03-15       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.